Opinion

Orphazyme provides regulatory update on arimoclomol for NPC

Arimoclomol, the company's lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic …

Read more

Show More

Related Articles

Back to top button